Drozitumab Biosimilar, Anti-human TRAIL Monoclonal Antibody | C044P

Catalog No.	C044P
Product Name	Drozitumab Biosimilar, Anti-human TRAIL Monoclonal Antibody | C044P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Tumour Necrosis Factor Related Apoptosis-inducing Ligand
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The Anti-human TRAIL monoclonal antibody drozitumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade drozitumab biosimilar specifically binds to death receptor DR5 and induces apoptosis.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by drozitumab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade drozitumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Drozitumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C044P: Drozitumab Biosimilar, Anti-human TRAIL Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab.

Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Please remember our product information: Drozitumab Biosimilar, TRAIL Monoclonal Antibody: C044P Syd Labs

No more offers for this product!